Evidence map›Paper›PMID 40316303›Full record

ArticleJournal for immunotherapy of cancer2025

RAC2 inhibition enhances tumor sensitivity to NK cell-mediated cytotoxicity.

Hui Guo, Jie Hu, Zining Wang, Feifei Xu, Yongxiang Liu, Lei Cui, Huanling Zhang, Chunyuan Xie, Ruhui Yao, Huan Jin and 7 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hui Guo *State Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Jie Hu *Department of Medical Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Zining WangState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Feifei XuDepartment of Oncology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Yongxiang LiuGuangzhou National Laboratory, Guangzhou, Guangdong, China.
Lei CuiState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Huanling ZhangGuangzhou National Laboratory, Guangzhou, Guangdong, China.
Chunyuan XieState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Ruhui YaoState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Huan JinState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Zixuan GuoState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Tiantian WangState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Lin LiState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Yanxun LinState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Xiaojuan WangState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Heping LiDepartment of Medical Oncology, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China xiaxj@sysucc.org.cn liheping@mail.sysu.edu.cn.
Xiaojun XiaState Key Laboratory of Oncology in South China, Department of Experiment Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China xiaxj@sysucc.org.cn liheping@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-4444-7472

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatural killer (NK) cells are recognized for their ability to kill tumor cells for tumor control, but tumor cells often develop resistance to evade NK cell-mediated cytotoxicity. Identification of molecular mechanisms by which tumor cells evade from NK cell-mediated killing may offer novel therapeutic strategies for potentiating NK-based cancer immunotherapy.

methodsAn in vitro tumor-NK cell co-culture system was employed to identify the most significantly altered genes in tumor cells following NK cell interaction. The cell death rate of tumor cells by NK cell exposure was quantified using flow cytometry. EL4 and HCT116 tumor models in C57BL/6, BALB/c-nu, and NOD/SCID mice were used for evaluating tumor growth differences induced by

resultsBy screening expression levels of the Ras homology (Rho) GTPase family genes in tumor cells after co-culture with NK cells, we identified RAC2 as a key regulator of tumor cell resistance to NK cell-mediated cytotoxicity among the Rho GTPase family members. Furthermore, knockout of

conclusionsThese findings indicate that the inhibition of RAC2 in tumor cells substantially enhances their susceptibility to NK cell-mediated cytotoxicity, thereby providing a potential therapeutic target for optimizing NK cell therapy.

Indexed as

Cytotoxicity, ImmunologicKiller Cells, Naturalrac GTP-Binding ProteinsAnimalsCell Line, TumorCoculture TechniquesHumansMiceMice, Inbred BALB CMice, Inbred C57BLMice, SCIDRAC2 GTP-Binding ProteinRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsImmunotherapyNatural killer - NK

Identifiers

PMID40316303
PMCPMC12049936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.